本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Oncolytics Biotech Inc

0.7455
-0.0265-3.43%
盤後0.75000.0045+0.60%19:40 EDT
成交量:120.37萬
成交額:90.33萬
市值:9,505.91萬
市盈率:-2.32
高:0.7745
開:0.7745
低:0.7305
收:0.7720
52周最高:1.51
52周最低:0.7301
股本:1.28億
流通股本:1.23億
量比:0.89
換手率:0.98%
股息:- -
股息率:- -
每股收益(TTM):-0.3215
每股收益(LYR):-0.3000
淨資產收益率:-10187.64%
總資產收益率:-211.24%
市淨率:-15.41
市盈率(LYR):-2.48

資料載入中...

2026/04/01

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2026/03/31

年度報告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2026/03/20

重要事件披露

Form 8-K - Current report
2026/03/19

重要事件披露

Form 8-K - Current report
2026/03/02

重要事件披露

Form 8-K - Current report
2026/02/24

重要事件披露

Form 8-K - Current report
2026/02/04

重要事件披露

Form 8-K - Current report
2026/01/15

重要事件披露

Form 8-K - Current report
2026/01/15

重要事件披露

Form 8-K - Current report
2026/01/12

重要事件披露

Form 8-K - Current report
2026/01/09

企業合併公告

Form 425 - Prospectuses and communications, business combinations
2025/12/06

SEC問詢函

Form CORRESP - Correspondence
2025/08/28

SEC問詢函

Form CORRESP - Correspondence
2025/03/07

年度報告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/06/04

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/03/12

年度報告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/03/03

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/03/03

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2021/03/05

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2021/03/05

財報披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]